Research / Rat NGAL ELISA

Rat NGAL ELISA Kit

Cat.No. KIT 046

An ELISA for the in vitro determination of rat NGAL in urine, plasma, serum, tissue extracts or culture media.
 
Target Rat NGAL (Neutrophil Gelatinase-Associated Lipocalin
Sample Type Rat urine, plasma or serum, tissue extracts or culture media
Cross reaction None
Numbers of tests 96 wells - 40 test in duplicate
Sample vol needed 10 µl
Dilution guideline 1/20,000 (Urine or EDTA plasma, healthy rats)
Assay range 4-400 pg/mL
Limit of Detection 0.5 pg/mL
Assay time <4 hours
Result type Quantitative (pg/mL)
Application For Research Use Only (RUO)

Rat NGAL - a biomarker of nephrotoxicity in drug development

Early kidney injury detection has been long sought and NGAL has recently been shown to be the biomarker that could fill this diagnostic gap. Measured from baseline, NGAL levels rise significantly in both urine and blood as a response to kidney injury - nephrotoxic, ischemic or otherwise.

Kit features

  • Simple ELISA format - easy to perform
    • Ready-to-use calibrators and working solutions
    • Pre-coated 96-well ELISA plate
    • All incubations performed at room temperature
  • Easy storage
    • All components are stored at 4°C
  • Automation possible on open ELISA workstations

Applicability

NGAL determination allows kidney injury to be detected almost as soon as it occurs, and not at the later stage when the consequences of impaired kidney function can be detected by existing routine tests and the damage has been consolidated.

Rats are among the most frequently used laboratory animals for research on kidney damage. The rat NGAL test can thus be used in the development of new treatments for kidney damage, to detect nephrotoxic side effects of new drugs, and for basic science research on kidney injury and kidney diseases.

The Rat NGAL ELISA Kit allows for the determination of rises in rat NGAL concentrations and hence the extent of renal injury, including nephrotoxic injury. For example in the following phases of drug development:

  • Discovery
  • Research and development
  • Pre-clinical phase